In Reply We thank Park for the comments on our study.1 We would like to point out that the Atopic Dermatitis Anti-IgE Pediatric Trial (ADAPT) did not set out to study the role of ultraviolet (UV) therapy in atopic dermatitis (AD) or compare it with omalizumab in children. The study on UV therapy2 quoted by Park was not a randomized clinical trial. Therefore, the results are not directly comparable and should be interpreted with caution.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chan S, Lack G. Comparing the Roles of Omalizumab and Ultraviolet Therapy in Treating Severe Pediatric Atopic Dermatitis—Reply. JAMA Pediatr. Published online June 15, 2020. doi:10.1001/jamapediatrics.2020.0969
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: